Nicoya Lifesciences Receives Additional Funding For Next-Phase Development Of Its Rapid, Saliva-Based Covid-19 Diagnostic Test
Nicoya Lifesciences Receives Additional Funding For Next-Phase Development Of Its Rapid, Saliva-Based Covid-19 Diagnostic Test
04/06/21, 9:40 PM
Location
kitchenerIndustry
mobile
Nicoya Lifesciences, a leading provider of advanced analytical instruments for the biotechnology and pharmaceutical industries, is pleased to announce that it is receiving additional advisory services and funding to continue research and development of its rapid, saliva-based COVID-19 antigen test. This is the second phase of support from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP). As part of a joint challenge issued with the Public Health Agency of Canada (PHAC) through the government's Innovative Solutions Canada (ISC) program, the funding could reach up to $1,998,592. To date, the company has received $299,190 in funding and advisory services from NRC IRAP under Phase I of the challenge.
Company Info
Location
kitchener, ontario, canada
Additional Info
Nicoya is a Canadian life sciences tools company specializing in innovative biosensor technology for the academic, biotechnology and pharmaceutical sectors. In their mission to improve human life, Nicoya provides scientists with user-friendly and integrated solutions that accelerate label-free biomolecular analysis. With their world-class expertise in nanotechnology and microfluidics, Nicoya is now helping hundreds of scientists succeed in over 50 countries. Information about Nicoya can be found at nicoyalife.com, on LinkedIn, Twitter, Facebook, and Instagram.